Targeting the upstream BTK kinase with different inhibitors, including Ibrutinib, blocks NFAT2 together with its targets including IL10; to note, IL10 can control PDL1 expression preferentially in the ABC subset of DLBCL thus suggesting that targeting NFAT may impact on the expression of this molecule, therefore being relevant for anti-tumor immunity (54). The gene discussed is IL10; the disease is diffuse large B-cell lymphoma.